摘要
结直肠癌是全世界范围内最常见的肿瘤之一,其血管生成过程受到血管内皮生长因子(VEGF)及其受体等血管生成因子的监控。由于在结直肠癌中抗血管生成药物的应用越来越广泛,有关预测血管生成抑制剂疗效标志物的研究也越来越多。这些标志物包括来源于组织和血液中的VEGF、基因多态性、循环肿瘤细胞和微RNA等。血管生成通路的复杂性以及血管生成因子的多样性对生物学标志物的探索提出了挑战。
Colorectal cancer is one of the most common tumors in the world. Angiogenesis is a tightly regulated process mediated by a group of angiogenic factors such as vascular endothelial growth factor（VEGF） and its receptors. Given the widespread use of antiangiogenic agents in colorectal cancer,there has been considerable interest in the development of methods to identify novel markers that can predict outcome in the treatment of this disease with angiogenesis inhibitors. Multiple biomarkers are in various phases of development,including tissue and serum VEGF,genetic polymorphism,circulating tumor cells and microRNA. The complexity of the angiogenesis pathway and the variety of the angiogenic factors present a significant challenge to biomarker discovery.
出处
《医学综述》
2017年第6期1118-1122,共5页
Medical Recapitulate
